Birth Control Pills and Thrombotic Risks: Differences of Contraception Methods with and without Estrogen.

@article{Rott2019BirthCP,
  title={Birth Control Pills and Thrombotic Risks: Differences of Contraception Methods with and without Estrogen.},
  author={Hannelore Rott},
  journal={Hamostaseologie},
  year={2019},
  volume={39 1},
  pages={
          42-48
        }
}
  • H. Rott
  • Published 22 January 2019
  • Medicine
  • Hamostaseologie
In Germany one-third of the women in fertile age use combined oral contraceptives (COCs), which consist mostly of ethinylestradiol (EE) and a synthetic progestin. Older COCs with norethisterone or levonorgestrel have a lower risk for venous thromboembolism (VTE) than newer COCs with desogestrel, drospirenone, or gestodene. This is also true for nonoral combined hormonal contraceptives. The risk of newer COCs containing estradiol instead of EE is not clear due to missing data. Progestin-only… 
8 Citations
Analysis of the Role of Female Hormones During Infection by COVID-19.
TLDR
Considering the hypercoagulability status of COVID-19, the debate about the use of contraceptives due to the relative risk of thromboembolic effects that they impose arises, but the current available evidence, as well as the recommendations of main health organs around the world, demonstrate that theUse of hormonal contraceptives must be maintained during the pandemic.
The risk of polypharmacy, comorbidities and drug–drug interactions in women of childbearing age with multiple sclerosis
TLDR
For the first time, a comprehensive range of potential DDIs in women of childbearing age with MS is presented and shows the need for effective and regular screening for such interactions in order to prevent avoidable adverse effects.
Venous Thromboembolism Requiring Anticoagulation Following Knee Arthroscopy in a Young Woman With an Intravaginal Contraceptive Device.
TLDR
A healthy, 30-year-old woman with a NuvaRing contraceptive device presented to the sports medicine clinic with knee pain, swelling, and mechanical symptoms, and her postoperative course was complicated by a rare deep venous thrombosis requiring anticoagulation therapy.
Hormonelle Kontrazeption und Thrombose
Hormonelle Kontrazeption und Thromboembolie-Risiko Kombinierte hormonelle Kontrazeptiva (KK) erhöhen das VTE-Risiko signifikant. Gestagen-Monopräparate sind mit Ausnahme der 3-Monatsspritze nicht
Hormonelle Kontrazeption und Thrombose
Hormonelle Kontrazeption und Thromboembolie-Risiko Kombinierte hormonelle Kontrazeptiva (KK) erhöhen das VTE-Risiko signifikant. Gestagen-Monopräparate sind mit Ausnahme der 3-Monatsspritze nicht
Retrospective analysis of risk factors for thrombotic events due to the use of combined oral contraceptives
TLDR
This document is intended to help clarify the role of data protection in the operation of this website and its intended uses.
Science Meets Clinical Practice.

References

SHOWING 1-10 OF 32 REFERENCES
Hormonal contraception--what kind, when, and for whom?
TLDR
As long as personal and familial risk factors are carefully considered, COCs constitute a safe, reversible, and well-tolerated method of contraception.
The Risk of Deep Venous Thrombosis Associated With Injectable Depot–Medroxyprogesterone Acetate Contraceptives or a Levonorgestrel Intrauterine Device
TLDR
The risk of venous thrombosis was increased for injectable depot–medroxyprogesterone acetate contraceptive users, while the authors were able to reliably exclude an increased risk associated with levonorgestrel intrauterine device use.
Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9
TLDR
Oral contraceptives with desogestrel, gestodene, or drospirenone were at least at twice the risk of venous thromboembolism compared with users of oral contraceptives with levonorgestrel.
Comparative Study of the Effects of Combined Oral Contraceptives in Hemostatic Variables
TLDR
It is suggested that the progestin drospirenone can contribute to an inadequate balance among procoagULant, anticoagulant, and fibrinolytic factors, since that the contraceptive containing the lowest dose of estrogen and drospitenone (DRSP/20EE) caused a higher number of hemostatic changes.
Association of Venous Thromboembolism With Hormonal Contraception and Thrombophilic Genotypes
TLDR
Except for injection of medroxyprogesterone acetate, progestin-only contraception seems to be the least thrombogenic hormonal contraception for women carrying genetic hemostatic variations.
Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
TLDR
In population based, case-control studies using two large primary care databases, risks of venous thromboembolism associated with combined oral contraceptives were, with the exception of norgestimate, higher for newer drug preparations than for second generation drugs.
Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study.
TLDR
The findings of this study support the presence of interaction between thrombophilia and venous thromboembolism among women taking oral contraceptives and hormone replacement therapy and further studies are required to establish with greater confidence the associations of these.
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10
TLDR
Women who use transdermal patches or vaginal rings for contraception have a 7.5 times increased risk of confirmed venous thrombosis compared with non-users of hormonal contraception of the same age, corresponding to 9.7 and 7.8 events per 10 000 exposure years.
Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism.
TLDR
The results show that the interaction between FVL and CHC use differ by progestin type, which is higher in CHC containing third-generation progestIn, drospirenone or cyproterone acetate, compared with second generation, and further studies are needed to assess the cost-effectiveness of biological thrombophilia screening (FVL).
...
1
2
3
4
...